Biotech company Cyxone has announced results from their phase II trial with drug candidate Rabeximod in patients with moderate to severe Covid-19. The data were inconclusive in terms of the effect of the drug candidate compared to standard of care treatment and Cyxone will now analyse the results further. In parallel, the company is preparing Rabeximod for a coming phase II trial in rheumatoid arthritis, the main focus for the candidate and Cyxone’s leading project. Tara Heitner, CEO, and Carl-Magnus Högerkorp, COO, visited the BioStock Studio to explain.
Watch the presentation and interview with Cyxone in the link below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.